DK0572437T3 - 2,4-diaminoquinazoline derivatives for enhancing antitumor action - Google Patents

2,4-diaminoquinazoline derivatives for enhancing antitumor action

Info

Publication number
DK0572437T3
DK0572437T3 DK92903632.5T DK92903632T DK0572437T3 DK 0572437 T3 DK0572437 T3 DK 0572437T3 DK 92903632 T DK92903632 T DK 92903632T DK 0572437 T3 DK0572437 T3 DK 0572437T3
Authority
DK
Denmark
Prior art keywords
antitumor action
enhancing antitumor
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
Prior art date
Application number
DK92903632.5T
Other languages
Danish (da)
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0572437T3 publication Critical patent/DK0572437T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Abstract

2,4-diaminoquinazoline derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.
DK92903632.5T 1991-02-20 1992-01-08 2,4-diaminoquinazoline derivatives for enhancing antitumor action DK0572437T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20

Publications (1)

Publication Number Publication Date
DK0572437T3 true DK0572437T3 (en) 1995-07-03

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92903632.5T DK0572437T3 (en) 1991-02-20 1992-01-08 2,4-diaminoquinazoline derivatives for enhancing antitumor action

Country Status (23)

Country Link
EP (1) EP0572437B1 (en)
JP (1) JPH06500117A (en)
KR (1) KR930703270A (en)
CN (1) CN1064271A (en)
AT (1) ATE121735T1 (en)
AU (1) AU655798B2 (en)
BR (1) BR9205645A (en)
CA (1) CA2101542A1 (en)
CZ (1) CZ387292A3 (en)
DE (2) DE9290018U1 (en)
DK (1) DK0572437T3 (en)
ES (1) ES2071484T3 (en)
FI (1) FI933656A (en)
HU (1) HUT64755A (en)
IE (1) IE920522A1 (en)
IL (1) IL100942A0 (en)
MX (1) MX9200675A (en)
NO (1) NO932954D0 (en)
NZ (1) NZ241627A (en)
PT (1) PT100132A (en)
WO (1) WO1992014716A1 (en)
YU (1) YU17092A (en)
ZA (1) ZA921911B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (en) * 1992-10-08 1994-10-16 Ici Plc A PHARMACEUTICAL COMPOSITION BASED ON QUINAZOLINE DERIVATIVES WITH ANTI-CANCERIGAN ACTIVITY.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE4429026C2 (en) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay removal instruments for total endoprosthesis
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507329A (en) * 1995-04-27 1999-06-29 ゼネカ リミテッド Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SI1676845T1 (en) 1999-11-05 2008-10-31 Astrazeneca Ab New quinazoline derivatives
AU2001240150A1 (en) * 2000-03-13 2001-09-24 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
SI1274692T1 (en) 2000-04-07 2006-12-31 Astrazeneca Ab Quinazoline compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
JP2007269629A (en) * 2004-06-21 2007-10-18 Astellas Pharma Inc Quinazoline derivative
AU2005269974A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-Met activity for the treatment of cancer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR20070117547A (en) * 2005-01-03 2007-12-12 미리어드 제네틱스, 인크. Method of treating brain cancer
EP1963284A1 (en) * 2005-12-07 2008-09-03 NeuroSearch A/S Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
CN101100466B (en) 2006-07-05 2013-12-25 天津和美生物技术有限公司 Non-reversible protein tyrosine phosphorus acylase inhibitor and its preparation and application
US20090004185A1 (en) * 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
WO2009001060A2 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
JP2013530942A (en) * 2010-05-07 2013-08-01 カリフォルニア・インスティチュート・オブ・テクノロジー Methods and compositions for inhibition of transitional endoplasmic reticulum ATPase
US11318137B2 (en) * 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
FI933656A0 (en) 1993-08-19
IE920522A1 (en) 1992-08-26
PT100132A (en) 1993-05-31
ATE121735T1 (en) 1995-05-15
NO932954L (en) 1993-08-19
FI933656A (en) 1993-08-19
DE9290018U1 (en) 1993-10-14
YU17092A (en) 1994-12-28
EP0572437B1 (en) 1995-04-26
ZA921911B (en) 1993-08-19
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
CZ387292A3 (en) 1994-04-13
AU1184892A (en) 1992-09-15
NO932954D0 (en) 1993-08-19
NZ241627A (en) 1993-06-25
ES2071484T3 (en) 1995-06-16
HUT64755A (en) 1994-02-28
HU9302384D0 (en) 1993-11-29
DE69202243D1 (en) 1995-06-01
DE69202243T2 (en) 1995-08-31
IL100942A0 (en) 1992-11-15
BR9205645A (en) 1994-06-07
JPH06500117A (en) 1994-01-06
CN1064271A (en) 1992-09-09
KR930703270A (en) 1993-11-29
EP0572437A1 (en) 1993-12-08
WO1992014716A1 (en) 1992-09-03
MX9200675A (en) 1992-08-01

Similar Documents

Publication Publication Date Title
DK0572437T3 (en) 2,4-diaminoquinazoline derivatives for enhancing antitumor action
YU47993B (en) 2,4-DIAMINOHINAZOLINA DERIVATIVES
YU39992A (en) 2,4-DIAMINOPYRIMIDINE DERIVATIVES
DE59006859D1 (en) DRILLING TABLE.
MX9200725A (en) ESOPHAGEAL CANCER TREATMENT. ESOPHAGEAL CANCER TREATMENT.
ES2001108A6 (en) Gem-dihalo-1,8-diamino-4-aza-octanes.
RU93054001A (en) 2,4-DIAMINOCHINAZOLINE DERIVATIVES, METHOD FOR PRODUCING THE PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING R-GLICOPROTEIN
FR2666406B1 (en) MINE, ESPECIALLY LAND MINE.
GR1001394B (en) 4-Ä4-Ä4-(4-hydroxyphenyl)-1-piperazinylÜphenyl-5-methyl-3h-1,2,4-triazol-3-one derivatives.
GR1001386B (en) Heterocyclic compounds.
MA21976A1 (en) THE SAVING TAP.